iBio, Inc. IBIO 深 沪
等待开盘 05-18 09:30:00 美东时间
1.47
-0.090
-5.77%
华盛通- 最 高1.54
- 今 开1.54
- 成交量 42.53万股
- 最 低 1.45
- 昨 收 1.56
- 总市值 7302.75万
- 52周最高 3.82
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 0.5562
- 委 比 1.64%
- 总股本 4967.86万
- 历史最高 17400.00
- 量 比 0.50
- 振 幅 5.77%
- 历史最低 0.5562
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多华盛早报 | 特朗普持仓大曝光！大额买入英伟达、苹果；SpaceX招股说明书据悉最快下周披露！
特朗普持仓大曝光！大额买入英伟达、苹果等；H200“松绑”落地！英伟达大涨逾4%创新高，联想已证实获准分销；SpaceX招股书最快下周披露！估值高达1.25万亿美元>>
05-15 08:26
华盛早报 | 恒科今日反攻？阿里、腾讯ADR绩后狂飙；党派分歧“史无前例”！沃什出任美联储主席
恒科今日反攻？阿里美股大涨逾8%，腾讯ADR涨近5%！双双上调AI资本开支；党派分歧“史无前例”！沃什出任美联储主席；半导体双雄中芯国际、华虹半导体即将放榜>>
05-14 08:33
港股早知道 | 中国AI用电料大增！算电协同受关注；阿里巴巴Q4云智能集团收入同比增38%
中国AI用电料大增！算电协同受关注；阿里巴巴Q4云智能集团收入同比增38%；腾讯Q1净利润同比增长21%>>
05-14 08:22
iBio Q3 EPS $(0.07) Misses $(0.06) Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 85.71 percent increase over losses of $(0.49) per share from the same
05-13 05:07
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
iBio, Inc. has appointed Elizabeth Stoner, M.D., M.S., as an independent member of its Board of Directors and to the Compensation Committee, following Eef Schimmelpennink's departure. Dr. Stoner brings over 35 years of experience in biotech research, development, and leadership, including roles at MPM BioImpact, Semma Therapeutics, and Rhythm Pharmaceuticals. Her expertise will support iBio’s first human clinical trial for treatments targeting ob...
05-08 11:15
iBio Advances to Clinical Stage With IBIO-600 Trial
Ibio ( ($IBIO) ) has shared an announcement. On April 8, 2026, iBio announced i...
04-08 21:47
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences, Inc. reported its financial results for Q4 and full year 2025, highlighting significant progress in advancing its next-generation cell and gene therapies powered by its Gene Circuit platform. The company achieved key milestones including positive clinical data for SENTI-202 in relapsed/refractory AML and FDA's RMAT designation. Despite challenges, Senti remains focused on disciplined execution to deliver innovative therapies. F...
03-27 12:00
iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026
iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET.
03-17 04:40
